24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
College Students Will Need COVID Tests Every 2-3 Days for Campus Safety: StudyAHA News: Sustained High Blood Pressure May Damage Brain VesselsAnother Side Effect of COVID-19 -- Lasting Hearing Problems?Pandemic Could Complicate Hurricane SeasonStudy Reveals How Coronavirus Travels IndoorsNew Study Sheds Doubt on Notion Kids Aren't COVID-19 SpreadersAHA News: Are Virtual Doctor Visits Safe for Discharged Heart Failure Patients?Double Lung Transplants Save Lives of Sickest COVID PatientsGynecological Cancers Not a Risk for Severe COVID-19: Study11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWildfire Pollution Puts Kidney Patients at RiskAmerica's Progress Against Early Cardiovascular Death Is SlowingAHA News: 5 Easy Ways to Keep Tabs on Heart HealthGene Study Shows How Coronavirus Swept Through the Diamond PrincessOne Disease Mosquitoes Don't Spread: CoronavirusU.S. Coronavirus Death Toll Surges Past 150,000Do Bedbugs Dirty the Air Inside Your Home?AHA News: New Test May Predict Who Develops Certain Type of Heart FailureLess Smoking, Drinking Means Fewer Hip Fractures for AmericansYet Another Study Finds Vaccines Are SafeCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationSurvivors' COVID Antibodies May Provide a Powerful GiftConcussion Ups Odds for Many Brain ConditionsFinal Coronavirus Vaccine Trials Get UnderwayAHA News: Flu Shot May Help Protect Vulnerable Hospital Patients From Heart Attack, Mini-StrokeCOVID-19 'Super Spreaders' Quickly Fill Room With Virus -- But Masks HelpIn Rush to Publish, Most COVID-19 Research Isn't Reliable, Experts SayGlaucoma Checkups Fall by the Wayside During PandemicLab-Created Virus Can Help COVID-19 Research, Developers SayHow to Counter the Anti-Mask Backlash? Empathy.States With Soaring COVID Cases Must Take Action, U.S. Health Officials SayWhat Puts You at High Risk of Midlife Mental Decline?AHA News: Controlling Diabetes Takes on Greater Urgency During COVID-19 PandemicMany U.S. Homes Too Cramped to Stop COVID-19's SpreadCDC Issues Call to Reopen America's Schools This FallMore Layers Are Better With Homemade Face MasksWith Safety Steps, Moms Unlikely to Pass COVID-19 to Newborns: StudyU.S. Coronavirus Cases Pass 4 Million, Third Day of Over 1,000 Deaths LoggedChronic Conditions Tied to Severe COVID-19 More Common in Southeast, Rural AreasSteroids Other Than Dexamethasone May Also Help Battle COVID-19COVID-19 Jitters Shouldn't Keep You From the Emergency RoomExpert Tips to Help You Beat the HeatEven Mild Obesity Raises Odds for Severe COVID-19U.S. Coronavirus Cases Near 4 Million as Death Toll Tops 1,000 for Second DayAntibodies Fade a Few Weeks After Mild COVID-19, Study FindsEarly Dialysis Doesn't Improve Outcomes With Acute Kidney FailureFor Cancer Patients, Getting COVID-19 Raises Death Risk 16-FoldStraight Talk From Front-Line Experts on Wearing a MaskCoronavirus Death Toll Tops 1,000 as Trump Warns the Worst is Still to ComeThyroid Drug May Not Help After Heart Attack: Study
Questions and AnswersLinks
Related Topics

Diabetes

Antibodies Fade a Few Weeks After Mild COVID-19, Study Finds

HealthDay News
by By E.J. Mundell
HealthDay Reporter
Updated: Jul 22nd 2020

new article illustration

WEDNESDAY, July 22, 2020 (HealthDay News) -- Hopes for robust, long-term antibody protection after a bout of COVID-19 have been dampened by a new study that finds the protection may only last a few months.

Still, experts noted that the body's immune system has more than one way to defend against viruses it has already encountered, so the findings don't dash hopes for a vaccine.

"Infection with this coronavirus does not necessarily generate lifetime immunity," Dr. Buddy Creech, an infectious disease specialist at Vanderbilt University in Nashville, told the Associated Press.

But antibodies are only part of the immune system's armamentarium, added Creech, who wasn't part of the new research.

The study was published July 21 in the New England Journal of Medicine. Researchers led by Dr. Otto Yang, of the University of California, Los Angeles, sought to determine the "half-life" of antibodies generated by contact with the new SARS-CoV-2 virus. Half-life means the time it takes for half of the antibodies to disappear.

Yang's group took blood samples from 34 people who had all recovered from a mild case of COVID-19. Twenty were women and 14 were men, and they averaged 43 years of age.

Based on blood tests collected up to 119 days after the onset of symptoms, the researchers said the half-life of antibodies linked with SARS-CoV-2 infection was just 36 days -- just over a month. At that rate, antibodies would disappear completely in about a year.

It's an "antibody loss [rate] that was quicker than that reported for SARS-CoV-1," the coronavirus responsible for the 2003 SARS outbreak, the researchers noted.

"Our findings raise concern that humoral [found in body fluids] immunity against SARS-CoV-2 may not be long lasting in persons with mild illness, who compose the majority of people with COVID-19," they said.

"Like the common cold-causing coronaviruses, the new coronavirus does not appear to provide durable antibody-based immunity for a long period of time," said Dr. Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security in Baltimore.

But that doesn't mean that immunity necessarily is gone, he added, since the human immune system has other tricks up its sleeve.

"It still remains to be seen whether these individuals can be reinfected and, if so, what that clinical course is like, as T-cell immunity is also an important factor to consider," said Adalja, who wasn't involved in the new study.

T-cells are a distinct component of what's known as the adaptive immune system. They help fight infection in many ways, including directly killing infected cells.

For his part, Creech agreed that just because antibodies to SARS-CoV-2 have a relatively short half-life doesn't mean people lose the ability to fight off recurrent infection.

He explained to the AP that antibodies are proteins produced by immune system B cells to help recognize and destroy cells infected with a virus. When a new virus is first encountered, more generalized forms of antibodies are quickly produced, but their specificity against the virus gets increasingly precise as time goes on.

The B cells also develop a kind of memory as to how to generate these precise antibodies if the virus appears in the body again.

"They would get called into action very quickly when there's a new exposure to the virus. It's as if they lie dormant, just waiting," Creech said. T-cells also lie in wait, able to mount a separate battle against infected cells, he said.

And what about hopes for a vaccine?

Efforts to find an effective vaccine are still valid, Creech said, because a vaccine's highly targeted approach against viruses actually exceeds that of the natural immune system.

"This shouldn't dissuade us from pursuing a vaccine," Creech said. "Antibodies are only a part of the story."

More information

For more on how the immune system works, see the U.S. Library of Medicine.